- By Ben Glickman
Viridian Therapeutics, a biotechnology company based in Waltham, Mass., witnessed a surge in its stock after the successful trial of a new formulation for treating thyroid eye disease (TED).
Stock Performance
- The stock experienced an 8.7% increase, reaching $20.88 during midday trading.
- However, the shares have faced a decline of 29% this year.
VRDN-003: A Promising Monoclonal Antibody Treatment
- Viridian Therapeutics introduced VRDN-003, a monoclonal antibody designed specifically for TED treatment.
- One notable advantage of VRDN-003 is its extended half-life of 40 to 50 days.
- This longer half-life is approximately four to five times longer than the company’s previous formulation, VRDN-001.
The Future of VRDN-003
- Due to its compelling performance, VRDN-003 has been chosen as the primary candidate for subcutaneous development of TED treatments.
- Viridian Therapeutics plans to commence the pivotal program for this treatment in mid-2024.
- The extended half-life of VRDN-003 allows for less frequent dosing, potentially reducing it to once every eight weeks.
Understanding Thyroid Eye Disease (TED)
- TED is an autoimmune disease that results in inflammation and swelling around the eye.